Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced the immediate appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group. He will be responsible for creating the Medical Affair’s strategy for the company’s oncology portfolio of both commercialized and investigational products in the United States. He will also oversee Eisai’s Health Economics & Outcomes Research (HEOR), Medical Science Liaisons (MSL) and Medical Information & Education teams.
“I am delighted to welcome Dr. Dezzani to Eisai to lead our U.S. Oncology Medical Affairs team,”
said Dr. Kirk Shepard, Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs for the Oncology Business Group.
“He comes to Eisai at an extraordinary time, as we dedicate our efforts towards the investigation of multiple modalities that we hope will harness the potential of the human immune system to result in more immunology in oncology, and, ultimately, benefit more patients.”
Dr. Dezzani joins Eisai from Novartis Oncology, where he held senior medical roles in Europe and the United States. His experience ranges across multiple disease areas in hematology and oncology, as well as rare diseases. He obtained his Medical Doctor (M.D.) degree from the University of Pavia in Italy, where he also completed his residency in internal medicine with specialized training in hematology and oncology.
“Eisai has the potential to transform cancer care, thanks to its innovative products, unique pipeline, and focus on immuno-modulation, which could play a crucial role in how we treat cancer and in improving outcomes for patients,”
said Dr. Dezzani.
“A modern and committed Medical Affairs department is instrumental in succeeding for patients, and I’m honored and excited to be joining Eisai in this journey.”
Over the past three decades, Eisai has been committed to the discovery and development of small molecules for the treatment of various difficult-to-treat cancers. Eisai’s current focus in oncology centers on tumor microenvironment modulation, the inhibition of pathways that inactivate the immune system, and cancer genomics.